The AlzeCure Research Foundation, formed by leading researchers from AstraZeneca, Swedish Brain Power’s director Bengt Winblad and the Alzheimer Foundation, is heading towards the stock market with it’s company AlzeCure Pharma AB.
The company is seeking further funding for research projects aimed at alleviating the symptoms of alzheimer’s disease and developing methods that affect the disease itself.
“At present there is no good medication for alzheimer’s. The market is gigantic, “says CEO Johan Sandin to Dagens Industri.
SEK 7 million has already been acquired for clinical studies and more is expected to come in conjunction with a stock market launch.